In a phase III trial in NSCLC patients with ALK mutations, the ALK inhibitor ceritinib significantly improved PFS compared to chemotherapy, suggesting potential efficacy for ROS1-mutant CCA patients as well [107]. Here, ALK is linked to cholangiocarcinoma.